Chennai-based Sai Mirra Innopharm raised ₹160 crore from Piramal Alternatives to fuel expansion, R&D, and brand acquisitions. With exports to more than 70 countries and a WHO-GMP certified facility, the pharma firm aims to enter new therapeutic segments. Founded in 2001, it’s now focused on global compliance, innovation, and high-growth areas like neurology, diabetes, and wellness.